Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R, Kanazu M, Kurebe H, Mori M, Fujimoto D, Taniguchi Y, Suzuki H, Hirano K, Yokoyama T, Morita M, Fukuda Y, Uchida J, Makio T, Tamiya M. Edahiro R, et al. Among authors: uchida j. PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019. PLoS One. 2019. PMID: 31365588 Free PMC article.
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer.
Minami S, Kijima T, Shiroyama T, Okafuji K, Hirashima T, Uchida J, Imamura F, Osaki T, Nakatani T, Ogata Y, Yamamoto S, Namba Y, Otsuka T, Tachibana I, Komuta K, Kawase I. Minami S, et al. Among authors: uchida j. BMC Res Notes. 2013 Jan 3;6:3. doi: 10.1186/1756-0500-6-3. BMC Res Notes. 2013. PMID: 23281805 Free PMC article. Clinical Trial.
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T, Kijima T, Otani Y, Nonen S, Namba Y, Mori M, Yokota S, Minami S, Komuta K, Uchida J, Imamura F, Furukawa M, Tsuruta N, Fujio Y, Azuma J, Tachibana I, Kumanogoh A. Takimoto T, et al. Among authors: uchida j. Clin Lung Cancer. 2013 Sep;14(5):502-7. doi: 10.1016/j.cllc.2013.03.003. Epub 2013 May 9. Clin Lung Cancer. 2013. PMID: 23664723
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y, Satouchi M, Katakami N, Fujita S, Kaji R, Hata A, Urata Y, Shimada T, Uchida J, Tomii K, Morita S, Negoro S. Hattori Y, et al. Among authors: uchida j. Cancer Chemother Pharmacol. 2014 Jan;73(1):17-23. doi: 10.1007/s00280-013-2290-y. Epub 2013 Oct 20. Cancer Chemother Pharmacol. 2014. PMID: 24141372 Clinical Trial.
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S. Otsuka T, et al. Among authors: uchida j. Anticancer Res. 2015 Jul;35(7):3885-91. Anticancer Res. 2015. PMID: 26124334
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A, Katakami N, Yoshioka H, Iwasaku M, Korogi Y, Hata A, Takeshita J, Otsuka K, Nishino K, Uchida J, Okuyama T, Namba Y, Mori M, Fujita S, Morita S. Nishiyama A, et al. Among authors: uchida j. Lung Cancer. 2015 Sep;89(3):301-5. doi: 10.1016/j.lungcan.2015.06.017. Epub 2015 Jun 25. Lung Cancer. 2015. PMID: 26141215
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M, Tamiya A, Hosoya K, Taniguchi Y, Yokoyama T, Fukuda Y, Hirano K, Matsumoto H, Kominami R, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Kinoshita Y, Hara S, Kumagai T, Fujimoto D. Tamiya M, et al. Among authors: uchida j. Invest New Drugs. 2019 Dec;37(6):1266-1273. doi: 10.1007/s10637-019-00843-y. Epub 2019 Aug 7. Invest New Drugs. 2019. PMID: 31392549
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, Fukuda Y, Yokoyama T, Kominami R, Fujimoto D, Hosoya K, Suzuki H, Hirashima T, Kanazu M, Sawa N, Uchida J, Morita M, Makio T, Hara S, Kumagai T. Kawachi H, et al. Among authors: uchida j. Invest New Drugs. 2020 Feb;38(1):211-218. doi: 10.1007/s10637-019-00882-5. Epub 2019 Nov 30. Invest New Drugs. 2020. PMID: 31784866
412 results